摘要
神经退行性疾病的一个共同特征是以酶抗性的蛋白质为主的错误折叠的形成。根据当前神经退行性疾病的理念这些物质可以形成有毒的组件。错折叠蛋白的重叠是这些疾病的典型特征。错折叠蛋白和有毒的聚集体的形成指向这些疾病的共同途径:ER应激和线粒体能量产生导致ER中正常蛋白质折叠的障碍。阿尔茨海默氏病(AD)是一种相当异质的,多因素疾病,其具有广泛的临床异质性,并且被分类成若干亚型。在AD中的淀粉样前体蛋白(APP)和有毒的β淀粉(Aβ)的结构的形成是非正常的。Aβ同时影响ER和线粒体,扰乱细胞的钙离子内稳态。线粒体功能障碍是AD的主要病理环节之一。线粒体积累来自ER /高尔基体或从相关的线粒体的ER-膜(MAM)衍生的Aβ。线粒体中自由基,氧化应激和增加钙-浓度使ATP的产生减少。由于Aβ的毒性线粒体动态和转运也被改变。突触线粒体表现出了非常高的隐患。钙水平在ER导致蛋白质折叠的功能障碍最终激活了折叠蛋白应答(UPR),并且还影响线粒体。MAM可以在ER线粒体交互中发挥特殊的作用。线粒体本身(使用线粒体靶向抗氧化剂如的MitoQ)可能是AD治疗一个特殊的目标。另一个目标是UPR级联蛋白(PERK、IRE1、ATF6)和ER(兰尼、IP3R)的参与稳定钙水平的受体。
关键词: β淀粉样蛋白,内质网,线粒体相关内质网膜,线粒体故障,突触线粒体,折叠蛋白应答。
Current Alzheimer Research
Title:Dysfunction of Endoplasmic Reticulum (ER) and Mitochondria (MT) in Alzheimer's Disease: The Role of the ER-MT Cross-Talk
Volume: 12 Issue: 7
Author(s): Katalin Volgyi, Gábor Juhász, Zsolt Kovacs and Botond Penke
Affiliation:
关键词: β淀粉样蛋白,内质网,线粒体相关内质网膜,线粒体故障,突触线粒体,折叠蛋白应答。
摘要: A common feature of neurodegenerative diseases is the formation of misfolded, mostly enzyme resistant proteins. These substances may form toxic assemblies according to the current concept of the neurodegenerative diseases. Overlapping of the misfolded proteins is typical in these disorders. The formation of misfolded proteins and toxic aggregates point to a common pathway of these disorders: failure in normal protein folding in the ER as a consequence of ER-stress and mitochondrial energy production. Alzheimer's disease (AD) is a rather heterogeneous, multifactorial disorder with wide clinical heterogeneity and is classified into several subtypes. In AD the processing of the amyloid precursor protein (APP) and formation of toxic β-amyloid (Aβ) structures occur intraneuronally. Aβ affects both ER and mitochondria and disturbs Ca2+-homeostasis of the cells. Mitochondrial dysfunction is one of the main pathological events in AD. Mitochondria accumulate Aβ derived from the ER/Golgi or from the mitochondriaassociated ER-membranes (MAM). Free radicals, oxidative stress and increasing Ca2+-concentration in mitochondria cause decreased ATP production. Mitochondrial dynamic and trafficking are also altered as a result of Aβ toxicity. Synaptic mitochondria show a very high vulnerability. Depletion of Ca2+ level in the ER results in dysfunction of protein folding and evokes unfolded protein response (UPR), and affects also mitochondria. MAM may play special role in the ERmitochondria cross talk. Mitochondria themselves (using mitochondria-targeting antioxidants such as MitoQ) could be a special target for AD treatment. Another targets are the UPR cascade proteins (PERK, IRE1, ATF6) and receptors involved in Ca2+ -level stabilization of the ER (Ryr, IP3R).
Export Options
About this article
Cite this article as:
Katalin Volgyi, Gábor Juhász, Zsolt Kovacs and Botond Penke , Dysfunction of Endoplasmic Reticulum (ER) and Mitochondria (MT) in Alzheimer's Disease: The Role of the ER-MT Cross-Talk, Current Alzheimer Research 2015; 12 (7) . https://dx.doi.org/10.2174/1567205012666150710095035
DOI https://dx.doi.org/10.2174/1567205012666150710095035 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alternative Splicing and Tumor Progression
Current Genomics Kaempferol-3-<i>O</i>-Rhamnoside Inhibits the Proliferation of Jurkat Cells Through Jun Amino-Terminal Kinase Signaling
The Natural Products Journal The Role of β-Amyloid Protein in Synaptic Function: Implications for Alzheimers Disease Therapy
Current Neuropharmacology Contribution of Catecholamine Reactive Intermediates and Oxidative Stress to the Pathologic Features of Heart Diseases
Current Medicinal Chemistry Role of ncRNAs in Development, Diagnosis and Treatment of Human Cancer
Recent Patents on Anti-Cancer Drug Discovery Altered Glutamate Neurotransmission and Behaviour in Dementia: Evidence from Studies of Memantine
Current Molecular Pharmacology Molecular Pathways Linking Inflammation and Cancer
Current Molecular Medicine Possible Physiopathological Effects of the Transglutaminase Activity on the Molecular Mechanisms Responsible for Human Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Bv8-Prokineticins and their Receptors: Modulators of Pain
Current Pharmaceutical Biotechnology Activation of Brain Endothelium by Soluble Aggregates of the Amyloid-β Protein Involves Nuclear Factor-κB
Current Alzheimer Research Small Molecule Antagonists of the Corticotropin Releasing Factor (CRF)Receptor: Recent Medicinal Chemistry Developments
Current Topics in Medicinal Chemistry Neurodegenerative Diseases of the Retina and Potential for Protection and Recovery
Current Neuropharmacology Vitamin D Analogs as Anti-Carcinogenic Agents
Anti-Cancer Agents in Medicinal Chemistry Canonical and Non-Canonical Barriers Facing AntimiR Cancer Therapeutics
Current Medicinal Chemistry Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments
Current Medicinal Chemistry Aurora Kinase Inhibitors in Head and Neck Cancer
Current Topics in Medicinal Chemistry Can Diet and Physical Activity Limit Alzheimer's Disease Risk?
Current Alzheimer Research Review: The Role of Radiolabeled DOTA-Conjugated Peptides for Imaging and Treatment of Childhood Neuroblastoma
Current Radiopharmaceuticals Parkinsons Disease: Genetics and Beyond
Current Neuropharmacology Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer
Current Drug Targets